Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Kipps, Thomas J. (UC San Diego Moores Cancer Center)
Fraser, Graeme (McMaster University (Canadà))
Coutre, Steven E (Stanford University School of Medicine)
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Barrientos, Jacqueline C. (Northwell Health Cancer Institute)
Barr, Paul M. (University of Rochester)
Byrd, John C. (The Ohio State University Comprehensive Cancer Center)
O'Brien, Susan M. (University of California)
Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque)
Hillmen, Peter (University of Leeds)
Jaeger, Ulrich (Medical University of Vienna)
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau)
Cramer, Paula (University of Cologne)
Stilgenbauer, Stephan (University of Ulm)
Chanan-Khan, Asher A. (Mayo Clinic Cancer Center)
Mahler, Michelle (Janssen Research and Development)
Salman, Mariya (Janssen Research and Development)
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company)
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company)
Balasubramanian, Sriram (Janssen Research and Development)
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company)
Londhe, Anil (Janssen Research and Development)
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company)
Howes, Angela (Janssen Research and Development)
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company)
Hallek, Michael (University of Cologne)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). We examined the pooled long-term follow-up data from PCYC-1115 (RESONATE-2), PCYC-1112 (RESONATE), and CLL3001 (HELIOS), comprising a total of 1238 subjects, to determine the prognostic significance of these markers in patients treated with ibrutinib. With a median follow-up of 47 months, ibrutinib-treated patients had longer progression-free survival (PFS) than patients treated in the comparator arm, regardless of genomic risk factors. Among patients treated with ibrutinib, we found that high-risk genomic features were not associated with shorter PFS (63-75% across all subgroups at 42 months) or overall survival (79-83% across all subgroups at 42 months). Surprisingly, we observed that ibrutinib-treated patients with del(11q) actually had a significantly longer PFS than ibrutinib-treated patients without del(11q) (42-month PFS rate 70% vs. 65%, P = . 02). These analyses not only demonstrate that genomic risk factors previously associated with poor outcomes lose their adverse prognostic significance but also that del(11q) can be associated with a superior PFS with ibrutinib therapy.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Prognostic factors ; Risk factors ; Small lymphocytic lymphoma ; Survival
Published in:	Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6, ISSN 2152-2669

DOI: 10.1016/j.clml.2019.07.004
PMID: 31447270

14 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles